October 5, 2004

Ambry Genetics Names Timothy Vo, PhD, FACMG Laboratory Director

IRVINE, CA (October 5, 2004) – AMBRY GENETICS, a leading genetic testing company, has named Timothy Vo, PhD as Laboratory Director. Dr. Vo will oversee the operation and supervision of the company’s molecular laboratory division.

“As we develop Ambry’s intellectual properties to further help the company’s growth, Dr. Vo’s extensive background and experience in instituting and establishing procedures for new diagnostic tests will prove invaluable” said Charles Dunlop, Chief Executive Officer of Ambry Genetics. “Tim has an excellent understanding of genomics and his perspective will be vitally important as the we continue to grow and develop our novel gene programs.”

Prior to joining Ambry Genetics, Dr. Vo was the Laboratory Director for Pathogenesys and served as the Associate Medical Director for US Labs both located in California where he validated and improved molecular methods studying genetics of inherited diseases and hematologic and solid tumor cancers. He has held director positions at Children’s Mercy Hospital in Kansas City and Harper Hospital in Detroit. He received his Ph.D. in Molecular Biology and Genetics and conducted his post-doctoral research studying Huntington’s Disease gene region at Wayne State University in Michigan. He earned his BS in Biology from University of California, Irvine.

AMBRY GENETICS

Ambry Genetics is a worldwide leader in specialized genetic testing. The proprietary Ambry Test™ combines scanning and sequencing technologies to analyze a gene’s entire coding region plus surrounding critical introns. Capable of identifying more than 99% of the known disease-causing mutations of the CFTR gene, the company’s reputable Cystic Fibrosis test has an unrivaled detection rate of over 96% across all ethnic groups. The Company also created the world’s first and only comprehensive genetic test for three principal genes (PRSS1, SPINK1 and CFTR) associated with Chronic and Hereditary Pancreatitis. Ambry Genetics most recent development detects mutations of the most significant genes (MLH1, MSH2) causing hereditary colon cancer, significantly optimizing patient management and risk assessment. Headquartered in Irvine, California, the Company’s advancements are providing precise, cost effective methods to aid in disease definition and early, more accurate diagnosis. Several academic and pharmaceutical research projects are underway, including expanded population statistical analysis and the development of assays for other genes. Website: www.ambrygen.com.